Arca
Skip to content
Tools
Tools

TACR1: Substance-P receptor

Receptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K.

  • Drugs that act on it: 16
  • Approved: 5
  • In phases 1 to 3: 11
  • Sponsors: 10

Who is on it, and how far along

Every drug ChEMBL records acting on TACR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 16

Approved5

  • Aprepitant
  • Fosaprepitant
  • Netupitant
  • Fosnetupitant
  • Rolapitant

Phase 34

  • Elinzanetant
  • Tradipitant
  • Casopitant
  • Serlopitant

Phase 27

  • Burapitant
  • DNK333
  • Ezlopitant
  • Figopitant
  • Orvepitant
  • Vestipitant
  • Vofopitant

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Neurokinin 1 receptor antagonist.
    AprepitantApprovedMerck & Co. (MSD)Small moleculeAntagonist18
    FosaprepitantApprovedQilu Pharmaceutical (Hainan)Small moleculeAntagonist16
    NetupitantApproved—Small moleculeAntagonist9
    FosnetupitantApprovedHelsinn HealthcareSmall moleculeAntagonist1
    RolapitantApprovedTerseraSmall moleculeAntagonist1
    ElinzanetantPhase 3BayerSmall moleculeAntagonist4
    TradipitantPhase 3Vanda PharmaceuticalsSmall moleculeAntagonist4
    CasopitantPhase 3GSKSmall moleculeAntagonist0
    SerlopitantPhase 3VYNE TherapeuticsSmall moleculeAntagonist0
    BurapitantPhase 2SanofiSmall moleculeAntagonist0
    DNK333Phase 2Novartis PharmaceuticalsSmall moleculeAntagonist0
    EzlopitantPhase 2—Small moleculeAntagonist0
    FigopitantPhase 2—Small moleculeAntagonist0
    OrvepitantPhase 2GSKSmall moleculeAntagonist0
    VestipitantPhase 2GSKSmall moleculeAntagonist0
    VofopitantPhase 2GSKSmall moleculeAntagonist0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 28 in all, from ClinicalTrials.gov.
    Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC TherapyNetupitantPhase 2Not yet recruitingFudan UniversityNov 5, 2026
    Prophylaxis for Emetogenic radioTherapy With AkynzeoNetupitantPhase 2Not yet recruitingUniversity Health Network, TorontoOct 20, 2026
    Chinese Herbal Acupoint Application Combined With Triple Antiemetic Therapy for Prevention of Chemotherapy-Induced Nausea and Vomiting in Breast CancerAprepitant, FosaprepitantPhase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of MedicineSep 30, 2026
    Aprepitant for the Treatment of CLIFAHDDAprepitant, FosaprepitantEarly phase 1RecruitingThe University of Texas Health Science Center at San AntonioSep 29, 2026
    QLM2010 Comparative Pharmacokinetic Study With 2-Minute Intravenous AdministrationAprepitant, FosaprepitantPhase 1Not yet recruitingQilu Pharmaceutical (Hainan) Co., Ltd.Sep 14, 2026
    Evaluation of Possible Ways the Body May Process Two Different Forms of Elinzanetant in Healthy Study ParticipantsElinzanetantPhase 1RecruitingBayerAug 13, 2026
    Fosrolapitant and Palonosetron for the Prevention of Antibody-drug Conjugate-induced Nausea and VomitingAprepitant, FosaprepitantPhase 2Not yet recruitingPeking University Cancer Hospital & InstituteJul 9, 2026
    A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving ChemotherapyAprepitant, NetupitantEarly phase 1Not yet recruitingOttawa Hospital Research InstituteJun 23, 2026
    Aprepitant to Improve Same Day Discharge for TKAAprepitantPhase 4Not yet recruitingEndeavor HealthJun 10, 2026
    An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause SymptomsElinzanetant—Not yet recruitingBayerMar 24, 2026
    An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HECFosaprepitantPhase 4RecruitingShanghai 6th People's HospitalMar 19, 2026
    Personalized Antiemetic Regimen According to Patients' Pharmacogenetic ProfileAprepitantPhase 2RecruitingChinese University of Hong KongMar 6, 2026
    A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist UseTradipitantPhase 3RecruitingVanda PharmaceuticalsMar 3, 2026
    A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and PalonosetronRolapitantNot applicableNot yet recruitingHenan Cancer HospitalMar 2, 2026
    Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing RegimenFosaprepitantPhase 3RecruitingThe Affiliated People's Hospital of Ningbo UniversityFeb 17, 2026
    Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic SurgeryAprepitantPhase 4RecruitingSir Mortimer B. Davis - Jewish General HospitalJan 28, 2026
    A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer PatientsNetupitantPhase 4Not yet recruitingTianjin Medical University Cancer Institute and HospitalNov 28, 2025
    NEPA in Patients With HER2-positive or HER2-low Advanced Breast Cancer Treated With T-DXdNetupitant—Enrolling by invitationYeon Hee ParkAug 20, 2025
    Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and VomitingFosaprepitantPhase 3Not yet recruitingThe First Affiliated Hospital of Xinxiang Medical CollegeAug 15, 2025
    Finding Links Between Hot flASHes and CardioVascular DiseaseElinzanetantPhase 2RecruitingMassachusetts General HospitalJul 22, 2025
    Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast CancerFosaprepitant, NetupitantPhase 3RecruitingJiuda ZhaoMay 1, 2025
    Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)FosnetupitantPhase 2RecruitingHelsinn Healthcare SAApr 1, 2025
    Akynzeo as Antiemetic Treatment in Patients With Endometrial CancerNetupitantPhase 4RecruitingFondazione IRCCS Istituto Nazionale dei Tumori, MilanoDec 10, 2024
    Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast CancerNetupitantPhase 3RecruitingJiuda ZhaoJan 10, 2024
    Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion SicknessTradipitantPhase 3Active, not recruitingVanda PharmaceuticalsNov 18, 2023
    Tradipitant for Functional DyspepsiaTradipitantPhase 2Enrolling by invitationXiao Jing (Iris) WangDec 16, 2022
    A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast CancerElinzanetantPhase 3Active, not recruitingBayerOct 20, 2022
    ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 InfectionTradipitantPhase 3Enrolling by invitationVanda PharmaceuticalsMar 30, 2020

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    • Cancer0.60
    • Chemotherapy-induced nausea and vomiting0.56
    • Post operative nausea and vomiting0.53
    • Neoplasm0.40
    • Atopic eczema0.38

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL249, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P25103, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Esc

    Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

    Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.